UTSW researchers neutralize genetic risk factor found in 50 to 80 percent of human cases
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.
Apolipoprotein E (ApoE) is a protein that carries fatty substances called lipids and cholesterol around the brain and plays an important role in repair mechanisms. There are three major forms of ApoE (i.e., ApoE2, ApoE3, and ApoE4); individuals who carry ApoE4 are up to 10 times more likely to develop Alzheimer’s than those with ApoE2 and ApoE3 forms. ApoE4 promotes accumulation of the b-amyloid protein that causes the characteristic plaques seen in the brains of Alzheimer’s patients.
UT Southwestern molecular biologist and Alzheimer’s expert Dr. Joachim Herz, lead author of the study, which was published in the November issue of eLife said the goal of his team is to prevent the disease from ever manifesting. Late-onset Alzheimer’s generally is diagnosed about age 65 and is the most common cause of dementia in the elderly. “If we can negate the ApoE4 process early, we may be able to prevent late-onset Alzheimer’s altogether for many people so that they will never get sick,” Dr. Herz said.
ApoE4 has been shown to suppress and trap synaptic receptors within intracellular vesicles. However, how the ApoE4 gets trapped has remained a mystery until now. According to Dr. Herz, ApoE4 is the root cause of a “traffic jam” inside the cells that take up ApoE4 and this is associated with reduced recycling of intracellular endosomal transport vesicles. UTSW researchers found that lowering the pH of these endosomes, i.e., by making them more acidic, cleared the traffic jam: The scientists were able to completely reverse the ApoE4-induced recycling block in mice through pharmacological and genetic inhibition of the NHE6 protein, which acts to make the endosomal vesicles less acidic.
These findings suggest a novel potential therapeutic approach for the prevention of late-onset Alzheimer’s disease, Dr. Herz said. The vesicle traffic jam due to the selective loss of solubility of ApoE4 likely is the earliest mechanism at which the protein negatively affects nerve cells, Dr. Herz said.
Most Alzheimer’s research has focused on halting the formation of amyloid and tau protein aggregates once they exist in the brain and degeneration has already begun. “Our approach in this study was to stop the overall degeneration process earlier; that is, before the formation of these aggregates,” Dr. Herz said.
The next step is to develop tailor-made, small molecule inhibitors that can enter the brain efficiently and selectively block NHE6, he added.
“The beauty of NHE inhibitors is that these are small molecules that can be produced inexpensively and thus made widely available, in contrast to the more elaborate antibody-based therapies that are currently being evaluated in clinical trials. A simple pill could someday neutralize the risk of late-onset Alzheimer’s disease just as readily available statins are able to reduce the risk of cardiovascular disease,” Dr. Herz said.
The Latest on: Late-onset Alzheimer’s
via Google News
The Latest on: Late-onset Alzheimer’s
- Alzheimer’s Disease Diagnostic Market Key Updates | World’s Top 10 Leaders Analysis, Revenue and Global Demand | Exclusive Reportage by MRFRon December 6, 2019 at 12:33 pm
On the basis of type, the Alzheimer’s disease diagnostic market has been segmented into early-onset Alzheimer’s disease, familial Alzheimer’s disease, and late-onset Alzheimer’s disease. On the basis ...
- Unprecedented evolutions emerging in Alzheimer's disease, related dementias researchon December 4, 2019 at 4:41 pm
NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) - A national genetics repository created by NIA to facilitate access by qualified investigators to genotypic data for the study of ...
- Alzheimer's Causing Gene Identifiedon December 3, 2019 at 1:07 am
Alzheimer's disease-inducing gene that may help explain a large part of the genetic risk has been discovered; this discovery might change the tide of research and may present a solution soon enough.
- Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugson December 2, 2019 at 10:16 am
Am J Med Genet Part B, Neuropsychiatr Genet. 2010;153B:185–201. Mukherjee S, Mez J, Trittschuh EH, Saykin AJ, Gibbons LE, Fardo DW et al. Genetic data and cognitively defined late-onset Alzheimer’s ...
- Alzheimer’s Disease Cure Might Be In Sighton November 28, 2019 at 12:19 am
A key insight uncovered by researchers from Harvard might lead to the development of drugs that can finally cure Alzheimer's disease.
- Calls to dementia helpline have DOUBLED since 2009 and surge 40% at Christmason November 27, 2019 at 4:01 pm
More than five million Americans have Alzheimer’s. It is unknown what causes Alzheimer's. Those who have the APOE gene are more likely to develop late-onset Alzheimer's. Mild Alzheimer's (early-stage) ...
- Study uncovers new Alzheimer's risk geneon November 21, 2019 at 2:54 am
A new paper in the Journal of Neuropathology & Experimental Neurology finds a gene that may help explain a large part of the genetic risk for developing Alzheimer's disease. Late-onset Alzheimer's ...
- New Alzheimer risk gene discoveredon November 21, 2019 at 12:04 am
A new paper in the Journal of Neuropathology & Experimental Neurology finds a gene that may help explain a large part of the genetic risk for developing Alzheimer disease. Late-onset Alzheimer disease ...
- Is There a Genetic Link to Alzheimer's Disease?on November 18, 2019 at 4:00 pm
They can also put us as higher risk for some diseases and health conditions. There are two types of Alzheimer's disease: early-onset and late-onset. Researchers believe there is a genetic component to ...
- Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Diseaseon November 12, 2019 at 2:46 am
Accounting for around 2 to 3% of AD cases, early onset Alzheimer's disease is a hereditary condition that is strongly linked with mutations in presenilin-1 (PSEN1), amyloid precursor protein (APP) and ...
via Bing News